Home › Funds › SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC › BBIO

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC position in BBIO

BRIDGEBIO PHARMA INC · Health Care

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC reported holding 450,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$29.6M, representing 0.88% of its reported portfolio and ranking #34 among its reported holdings. SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC has disclosed BBIO holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

Latest position (Q3 2026)450.00K sh
Reported value held$29.61M
Portfolio Weight0.88%
First reportedQ1 2025
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC's BBIO position evolved

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC first disclosed a stake in BBIO in Q1 2025 at 1,129,592 shares (US$39.0M). The position peaked in Q4 2025 at 813,794 shares, worth US$62.2M. Across 7 filings, SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 450,000 shares valued at US$29.6M — a reduction of -171,125 shares quarter over quarter.. Notable position changes include a 33% trim in Q2 2025 (shares rose 20% over the following quarter), a 82% trim in Q1 2026 (shares were roughly flat over the following quarter), a 314% increase in Q2 2026 (shares fell 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 1.13M $39.05M New
Q2 2025 757.75K $32.72M Reduce
Q3 2025 806.71K $41.90M Add
Q4 2025 813.79K $62.25M Add
Q1 2026 150.00K $11.14M Reduce
Q2 2026 621.12K $46.26M Add
Q3 2026 450.00K $29.61M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 42 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC held BBIO?

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC has disclosed BBIO holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

What is SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC's current position in BBIO?

As of Q3 2026, SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds 450.00K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $29.61M, representing 0.88% of its reported portfolio and ranking #34.

Has SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC been buying or selling BBIO?

In the latest 13F filing (Q3 2026), SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC reduced its position in BBIO. The position peaked in Q4 2025 at 813.79K shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, FARALLON CAPITAL MANAGEMENT, L.L.C., among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.